OCT 15·BenzingaMed
60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study - 60 Degrees ( NASDAQ:SXTPW ) , 60 Degrees ( NASDAQ:SXTP )
Breakthrough Therapy Designation request has been submitted to FDA Company to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application ( sNDA ) Results obtained using highest sensitivity test available. licensed by FDA for blood donation ...